SOURCE: SECFilings.com

SECFilings.com

September 29, 2016 08:58 ET

Endonovo at the Intersection of Stem Cells and Biologics for Next Generation Therapeutics - SECFilings.com

REDONDO BEACH, CA--(Marketwired - Sep 29, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article covering the unique technology that Endonovo Therapeutics (OTCQB: ENDV) is applying in the development of biologics and stem cells.

Biologics, which differ from traditional drugs, as they are complex molecules typically derived from an array of living organisms rather than being synthesized chemicals, have become a hot area for big pharma in recent years, led by blockbusters like AbbVie's Humira, which generated a jaw-dropping $14.1 billion in sales in 2015, Roche's Rituxan ($7.3 billion in 2015 sales) and Sanofi's Lantus ($7.1 billion in 2015 sales).

Clearly, all the big boys have come to the biologics table looking to get their share of a market that IMS Health analysts estimate will rise to $390 billion by 2020, meaning that biologics will command nearly one-third of all spending on drugs in the next few years.

With the space becoming ever-more competitive and several key patent expirations on the horizon, it won't be surprising to see big pharma look to smaller firms with innovations in the biologic space to try and get an edge with next generation therapies. That is where Endonovo Therapeutics is positioning itself by patenting and developing its Cytotronics platform. While most biologics are formed using recombinant-DNA technology, Endonovo is taking a different route to produce biologics.

Endonovo's platform, which has its roots going back to stem cell work at NASA to help keep astronauts healthy during extended periods in microgravity, uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, to produce fully human biologics, and to "train" stem cells to act as tiny drug factories. It does so primarily through stimulation of magnetically induced electrical field pathways of cells and tissues.

Read the full article on SECFilings.com here: http://analysis.secfilings.com/articles/74-endonovo-at-the-intersection-of-stem-cells-and-biologics-for-next-generation-therapeutics

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

Contact Information